EP1263765A4 - Modification de comportement cellulaire par modulation antisens de la maturation d'arn messager - Google Patents

Modification de comportement cellulaire par modulation antisens de la maturation d'arn messager

Info

Publication number
EP1263765A4
EP1263765A4 EP00919726A EP00919726A EP1263765A4 EP 1263765 A4 EP1263765 A4 EP 1263765A4 EP 00919726 A EP00919726 A EP 00919726A EP 00919726 A EP00919726 A EP 00919726A EP 1263765 A4 EP1263765 A4 EP 1263765A4
Authority
EP
European Patent Office
Prior art keywords
alteration
mrna processing
antisense modulation
cellular behavior
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00919726A
Other languages
German (de)
English (en)
Other versions
EP1263765A1 (fr
Inventor
C Frank Bennett
Stanley T Crooke
Muthiah Manoharan
Jacqueline R Wyatt
Brenda F Baker
Brett P Monia
Susan M Freier
Robert Mckay
James G Karras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of EP1263765A1 publication Critical patent/EP1263765A1/fr
Publication of EP1263765A4 publication Critical patent/EP1263765A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne des compositions et des procédés permettant de commander le comportement d'une cellule, d'un tissu ou d'un organisme, par modulation antisens de la maturation d'ARN messager, impliquant l'utilisation de composés antisens qui n'assurent pas le clivage de la cible d'ARN messager.
EP00919726A 2000-03-28 2000-03-28 Modification de comportement cellulaire par modulation antisens de la maturation d'arn messager Withdrawn EP1263765A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/008174 WO2001072765A1 (fr) 2000-03-28 2000-03-28 Modification de comportement cellulaire par modulation antisens de la maturation d'arn messager

Publications (2)

Publication Number Publication Date
EP1263765A1 EP1263765A1 (fr) 2002-12-11
EP1263765A4 true EP1263765A4 (fr) 2005-06-29

Family

ID=21741209

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00919726A Withdrawn EP1263765A4 (fr) 2000-03-28 2000-03-28 Modification de comportement cellulaire par modulation antisens de la maturation d'arn messager

Country Status (5)

Country Link
EP (1) EP1263765A4 (fr)
JP (1) JP2004509604A (fr)
AU (2) AU2000240366B2 (fr)
CA (1) CA2400573A1 (fr)
WO (1) WO2001072765A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020097241A (ko) 2000-05-04 2002-12-31 에이브이아이 바이오파마 인코포레이티드 스플라이스-영역 안티센스 조성물 및 방법
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
EP2336319A1 (fr) * 2002-11-13 2011-06-22 Genzyme Corporation Modulation anti-sens d'expression B apolipoprotéine
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
WO2004044181A2 (fr) * 2002-11-13 2004-05-27 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression d'apolipoproteine b
JP4762889B2 (ja) * 2003-03-12 2011-08-31 バスジーン セラピューティクス，インコーポレイテッド 血管形成及び腫瘍成長を阻止するための核酸化合物
US20050222068A1 (en) 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
EP1711606A2 (fr) * 2004-01-20 2006-10-18 Isis Pharmaceuticals, Inc. Modulation de l'expression du r cepteur glucocortico de
WO2005072527A2 (fr) 2004-01-23 2005-08-11 Avi Biopharma, Inc. Oligomeres antisens et methodes destinees a induire la tolerance immunitaire et l'immunosuppression
US20050287558A1 (en) 2004-05-05 2005-12-29 Crooke Rosanne M SNPs of apolipoprotein B and modulation of their expression
EP3228711A1 (fr) 2004-06-28 2017-10-11 The University Of Western Australia Oligonucléotides antisens permettant d'induire un saut d'exon et leurs procédés d'utilisation
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
AU2007257093A1 (en) 2006-05-05 2007-12-13 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of PCSK9
CN103480002A (zh) 2007-03-24 2014-01-01 基酶有限公司 施用与人载脂蛋白 b互补的反义寡核苷酸
CA2710013A1 (fr) 2007-12-28 2009-07-09 Avi Biopharma, Inc. Agents immunomodulatoires et procedes d'utilisation
CN105779453A (zh) 2008-10-24 2016-07-20 萨雷普塔治疗公司 用于dmd的多外显子跳跃组合物
WO2010080554A1 (fr) 2008-12-17 2010-07-15 Avi Biopharma, Inc. Compositions antisens et méthodes de modulation de l'hypersensibilité de contact ou de la dermatite de contact
EP2408796B1 (fr) 2009-03-16 2020-04-22 Ionis Pharmaceuticals, Inc. Ciblage de l'Apolipoprotéine B pour la réduction de l'apolipoprotéine C-III
JP5963678B2 (ja) 2009-11-12 2016-08-03 ジ ユニバーシティ オブ ウェスタン オーストラリア 病状を治療するためのアンチセンス分子及び方法
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
JP6105041B2 (ja) 2012-03-28 2017-03-29 エシコン・エンド−サージェリィ・インコーポレイテッドＥｔｈｉｃｏｎ Ｅｎｄｏ−Ｓｕｒｇｅｒｙ，Ｉｎｃ． 低圧環境を画定するカプセルを含む組織厚コンペンセーター
JP6492003B2 (ja) * 2012-03-30 2019-03-27 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 発作を減少させるためおよび神経変性症候群を改質するためにタウ発現を調節する方法
EP2850186B1 (fr) 2012-05-16 2018-12-19 Translate Bio MA, Inc. Compositions et procédés de modulation de l'expression de la famille génique smn
AU2013262709A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
JP6449231B2 (ja) 2013-03-14 2019-01-09 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィを処置するためのエキソンスキッピング組成物
CN111254145A (zh) * 2013-03-14 2020-06-09 Ionis制药公司 用于调节tau表达的组合物和方法
MX2015013117A (es) 2013-03-15 2016-07-14 Sarepta Therapeutics Inc Composiciones mejoradas para tratar distrofia muscular.
EP2986599A1 (fr) 2013-04-17 2016-02-24 Pfizer Inc. Dérivés de n-pipéridin-3-ylbenzamide dans le traitement des maladies cardiovasculaires
TW202246503A (zh) 2013-07-19 2022-12-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
WO2015051283A1 (fr) 2013-10-04 2015-04-09 Rana Therapeutics, Inc. Compositions et méthodes pour traiter la sclérose latérale amyotrophique (sla)
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
JOP20190065A1 (ar) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000008044A1 (fr) * 1998-08-07 2000-02-17 Isis Pharmaceuticals, Inc. Oligonucleotides 2'-o-aminoethyloxyethyle-modifies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100252547B1 (ko) * 1991-09-05 2000-09-01 프레드 마리얀스키 폴리-또는 올리고누클레오티드의 세포로의 표적화된 전달
CA2162361C (fr) * 1993-05-11 2008-10-21 Ryszard Kole Oligonucleotides antisens actifs contre l'epissage aberrant; methodes d'utilisation
US6040296A (en) * 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
US5776905A (en) * 1996-08-08 1998-07-07 The Board Of Trustees Of The Leland Stamford Junior University Apoptotic regression of intimal vascular lesions
US6214986B1 (en) * 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000008044A1 (fr) * 1998-08-07 2000-02-17 Isis Pharmaceuticals, Inc. Oligonucleotides 2'-o-aminoethyloxyethyle-modifies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAKER B F ET AL: "2'-O-(2-METHOXY)ETHYL-MODIFIED ANTI-INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1) OLIGONUCLEOTIDES SELECTIVELY INCREASE THE ICAM-1 MRNA LEVEL AND INHIBIT FORMATION OF THE ICAM-1 TRANSLATION INITIATION COMPLEX IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 272, no. 18, 2 May 1997 (1997-05-02), pages 11994 - 12000, XP002948752, ISSN: 0021-9258 *
See also references of WO0172765A1 *
SIERAKOWSKA HALINA ET AL: "Restoration of beta-globin gene expression in mammalian cells by antisense oligonucleotides that modify the aberrant splicing patterns of thalassemic pre-mRNAs", NUCLEOSIDES AND NUCLEOTIDES, vol. 16, no. 7-9, July 1997 (1997-07-01), pages 1173 - 1182, XP008042383, ISSN: 0732-8311 *

Also Published As

Publication number Publication date
JP2004509604A (ja) 2004-04-02
CA2400573A1 (fr) 2001-10-04
AU4036600A (en) 2001-10-08
AU2000240366B2 (en) 2005-08-04
EP1263765A1 (fr) 2002-12-11
WO2001072765A1 (fr) 2001-10-04

Similar Documents

Publication Publication Date Title
EP1263765A4 (fr) Modification de comportement cellulaire par modulation antisens de la maturation d'arn messager
WO1999043651A3 (fr) Inhibiteurs d'enzymes phospholipases
WO2004018058A3 (fr) Composes, compositions et methodes
WO2005028443A3 (fr) Inhibiteurs de l'enzyme de la proteine tyrosine kinase
WO2005023824A3 (fr) Procedes d'inhibition de la proliferation de cellules tumorales
WO2004009036A3 (fr) Composes, compositions et procedes
AU2002350228A1 (en) Antisense modulation of myd88 expression
AU2002252255A1 (en) Improved double chamber ion implantation system
WO2002073208A3 (fr) Agents antiepileptogenes
AU2003268096A1 (en) ANTISENSE MODULATION OF Nav1.3 EXPRESSION
BR0110689B1 (pt) composiÇço fungicida, e, mÉtodos para intensificar a atividade fungicida de etaboxam, e para controlar fitopatàgenos indesejados.
WO2004026226A3 (fr) Composes, compositions et procedes
WO2004034972A3 (fr) Composes, compositions, et procedes
EP1144690A4 (fr) Modulation antisens de l'expression d'un inhibiteur cellulaire d'apoptose-2
WO2003035667A3 (fr) Interference avec l'activite de la telomerase
EP1163373A4 (fr) Modulation antisens de l'inhibiteur cellulaire de l'expression de l'apoptose-1
AU2003257966A1 (en) Antisense modulation of lar expression
WO2005115456A3 (fr) Procede de modulation du systeme endocrinien de reproduction par modulation de l'activite de tnf-$g(a)
WO2002047604A3 (fr) Utilisation des composes de la classe des chalcones pour inhiber la vascularisation d'une masse tumorale
WO2004003152A3 (fr) Inhibiteurs de sos1
AU2002232521A1 (en) Compositions and methods for identifying agents which regulate chromosomal stability, gene activation and aging
AU2001285916A1 (en) Nucleotide sequences which code for the clpc gene
WO2004024086A3 (fr) Composés, compositions et méthodes
WO2002008183A3 (fr) Inhibiteurs de canaux a potassium
AU2002325305A1 (en) Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020919

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ISIS PHARMACEUTICALS, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 15/86 B

Ipc: 7C 12Q 1/68 B

Ipc: 7A 01N 43/04 B

Ipc: 7C 12N 15/85 B

Ipc: 7C 12N 15/11 B

Ipc: 7A 61K 31/70 B

Ipc: 7C 07H 21/04 B

Ipc: 7C 07H 21/02 A

A4 Supplementary search report drawn up and despatched

Effective date: 20050511

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ISIS PHARMACEUTICALS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050721